These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7666905)

  • 1. Is the use of t-PA as compared with streptokinase cost effective?
    Armentano R; Favaloro RG
    N Engl J Med; 1995 Oct; 333(15):1009-10. PubMed ID: 7666905
    [No Abstract]   [Full Text] [Related]  

  • 2. Is the use of t-PA as compared with streptokinase cost effective?
    Rose EA
    N Engl J Med; 1995 Oct; 333(15):1009; author reply 1010. PubMed ID: 7666904
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.
    Massel D
    Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Are the publicized advantages of thrombolytic treatment of myocardial infarct with recombinant t-PA (ACTILYSE) in comparison with streptokinase so decisive, that despite the high cost a general use of ACTILYSE is justified?].
    Gulba DC
    Internist (Berl); 1992 May; 33(5):364-5. PubMed ID: 1612871
    [No Abstract]   [Full Text] [Related]  

  • 7. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thrombolytic therapy].
    de Gaetano G; Donati MB; Gensini GF; Restagno C
    Recenti Prog Med; 1993 Sep; 84(9):581-5. PubMed ID: 8210621
    [No Abstract]   [Full Text] [Related]  

  • 9. Myocardial infarction, thrombolytic therapy, and economics.
    Shander D
    Clin Cardiol; 1993 Nov; 16(11):845. PubMed ID: 8269667
    [No Abstract]   [Full Text] [Related]  

  • 10. [Myocardial infarction treated within 4 hrs: comparison of the cost-benefit ratio of 3 thrombolytic treatments: APSAC, rt-PA and streptokinase in 270 patients].
    Machecourt J; Cassagnes J; Bassand JP; Dumoulin J; Calop J; Foroni L; Terrisse MP; Hénon T; Petit L; Denis B
    Arch Mal Coeur Vaiss; 1993 Feb; 86(2):209-17. PubMed ID: 8363422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolytic therapy for acute myocardial infarction: GUSTO criticized.
    Friedman HS
    N Engl J Med; 1994 Feb; 330(7):504; author reply 505-6. PubMed ID: 8289861
    [No Abstract]   [Full Text] [Related]  

  • 13. [Tissue plasminogen activator is the best thrombolytic agent].
    Bates E
    Arq Bras Cardiol; 1994 Jul; 63(1):57-8. PubMed ID: 7857215
    [No Abstract]   [Full Text] [Related]  

  • 14. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction.
    Naylor CD; Bronskill S; Goel V
    Can J Cardiol; 1993; 9(6):553-8. PubMed ID: 8221354
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost effectiveness of tissue plasminogen activator.
    Lee TH
    N Engl J Med; 1995 May; 332(21):1443-4. PubMed ID: 7723804
    [No Abstract]   [Full Text] [Related]  

  • 17. Early patency in acute myocardial infarction.
    Belenkie I
    Can J Cardiol; 1993 Mar; 9(2):149-51. PubMed ID: 8490781
    [No Abstract]   [Full Text] [Related]  

  • 18. [Thrombolytic therapy of acute myocardial infarction].
    Chen JL
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(1):69-70. PubMed ID: 15808085
    [No Abstract]   [Full Text] [Related]  

  • 19. [Fibrinolytic treatment of myocardial infarction. Introduction].
    Kawecka-Jaszcz K
    Przegl Lek; 1992; 49(9):310-11. PubMed ID: 1302357
    [No Abstract]   [Full Text] [Related]  

  • 20. Dealing with discounting. An application to the cost-effectiveness of intracoronary thrombolysis with streptokinase.
    Martens L; van Doorslaer E
    Int J Technol Assess Health Care; 1990; 6(1):139-45. PubMed ID: 2113890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.